Q2 2026 Cigna Group Earnings Call Transcript
Key Points
- Strong second-quarter performance with adjusted EPS of $7.78, leading to an increased full-year 2026 adjusted EPS outlook to at least $30.45.
- Evernorth's Specialty and Care Services delivered 22% year-over-year pretax adjusted earnings growth, driven by specialty utilization and biosimilar adoption.
- Cigna Healthcare exceeded expectations with 17% pretax adjusted earnings growth, supported by disciplined pricing and strong US employer business performance.
- The new Signature rebate-free PBM model is generating significant early interest from clients, with a strong 2027 selling season showing new business secured above the prior two years combined.
- AI and technology initiatives, such as Pharmacy Forward and AI-enabled care coordination, are improving patient outcomes and reducing costs, with early engagement yielding a 42% reduction in avoidable inpatient stays.
- Pharmacy Benefit Services earnings declined year-over-year due to large client contract renewals and investments in the Signature model transition.
- GLP-1 volume growth moderated in the second quarter, creating a modest headwind for Evernorth, with expectations of continued slower growth in the second half.
- Medical cost trends remain elevated in the high single digits, with no significant deceleration, posing ongoing affordability challenges.
- The IDR (Independent Dispute Resolution) mechanism is seeing unsustainable volume levels and favoring providers, exacerbating affordability pressures for employers and health plans.
- The planned exit from the individual exchange business will result in stranded overhead costs and a modest capital release, impacting 2027 results.
Ladies and gentlemen, thank you for standing by for The Cigna Group's second-quarter 2026 results review. (Operator Instructions)
As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.
Great. Thank you. Good morning, everyone. Thanks for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are Brian Evanko, The Cigna Group's President and Chief Executive Officer; and Ann Dennison, Chief Financial Officer.
In our remarks today, Brian and Ann will cover a number of topics, including our second-quarter 2026 financial results and our financial outlook for 2026. Following their prepared remarks, Brian and Ann will be available for Q&A.
As noted in our earnings release, when describing our financial results, we use certain financial measures, including adjusted income from operations and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
